Letters to the Editor
Case Report: Use of Prazosin for Treatment of Posttraumatic Stress Disorder
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2005 Sep 1;72(5):758-761.
to the editor: Nearly two full years after the events of September 11, 2001, I was consulted at a rural community mental health center on a 38-year-old male former emergency relief worker who was present for the cleanup after the collapse of the Twin Towers in New York City. He continued to experience severe sleep disturbance despite multiple medication trials including a selective serotonin reuptake inhibitor (SSRI), a mood stabilizer, and an atypical antipsychotic. Many of his other symptoms of posttraumatic stress disorder (PTSD), including “wild nightmares,” irritability, and reexperiencing scents and colors, had waned over two years, during which he also had undergone therapy to include Eye Movement Desensitization Response (EMDR). Other than an exhausted appearance, he had a normal mental status examination.
As presented so clearly by Dr. Grinage in the American Family Physician article, “Diagnosis and Management of Posttraumatic Stress Disorder,”1 PTSD is a compelling disorder that can severely disrupt a person’s premorbid lifestyle with intrusive thoughts, nightmares, sleep disturbance, irritability, and a plethora of other potentially disabling effects. One report2 demonstrated relief of nightmares in two veterans who were being treated with prazosin (Minipress) for benign prostatic hypertrophy. Subsequently, this was repeated successfully for five civilian trauma victims in another study3 and replicated in a placebo-controlled trial4 in 10 additional veterans. As noted by Raskind and colleagues,2 prazosin is a centrally active alpha1-adrenergic antagonist that should reduce excessive brain noradrenergic activity. The use of prazosin is likely to be familiar to family physicians given its past popularity in the treatment of patients with hypertension.
After warning the patient about the potentially significant first-dose effect of orthostatic hypotension, a trial of prazosin was initiated at 1 mg before bedtime. At follow-up, he reported excellent sleep, with no nightmares since the third week of the trial. He had experienced one minor spell of lightheadedness and some mild morning grogginess. He appeared well rested and in good condition. No dose escalation was required.
Prazosin should be considered in the treatment of the otherwise healthy patient with PTSD, if other standard treatments such as cognitive therapy and SSRIs have failed to relieve the sleep disturbance.
1. Grinage BD. Diagnosis and management of post-traumatic stress disorder. Am Fam Physician. 2003;68:2401–8.
2. Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry. 2000;61:129–33.
3. Talyor F, Raskind MA. The alpha1-antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22:82–5.
4. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin. Am J Psychiatry. 2003;160:371–3.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions